Reproducibility Initiative Shrinks

Budget issues are limiting the number of studies the Reproducibility Project: Cancer Biology will try to re-do.

Written byKerry Grens
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

WIKIMEDIA, NATIONAL CANCER INSTITUTEThe Reproducibility Project: Cancer Biology originally intended to replicate 50 high-impact cancer papers in an effort to get some sense of how often scientific results are repeatable. But as Nature News reported yesterday (December 2), that number is scaling back to 37.

According to the news report, the project had estimated each study would cost $25,000 to $35,000, but as things got moving the costs became closer to $40,000 per replicated study.

“I don’t think that was truly appreciated at the beginning of the project,” Tim Errington, a project manager at the Center for Open Science, which is coleading the project, told Nature News. “The best thing for us to do is move forward with what we have.”

The 13 culled papers hadn’t made much progress so far and included animal experiments, which can be expensive.

Some expressed disappointment at the reduction. “Bad news, was looking forward to this,” @PubPeer tweeted. Others have criticized the reproducibility initiative for being marked with “a naiveté that by simply embracing ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies